Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0172-0179

  Nakou, Magda ^a   Papadimitraki, Eva D ^a   Fanouriakis, Antonios ^a   Bertsias, George K ^a   Choulaki, Christianna ^a   Goulidaki, Nektaria ^a   Sidiropoulos, Prodromos ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Autoimmunity; Cytokines; Immunoglobulin; Plasma cells; T cells

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; MESSENGER RNA; TOLL LIKE RECEPTOR 9; BIOLOGICAL MARKER; CD19 ANTIGEN; CD27 ANTIGEN; CPG ODN 2006; IL21R PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 21 RECEPTOR ALPHA; INTERLEUKIN DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; MALE; MEMORY CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; APOPTOSIS; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, CD19; ANTIGENS, CD27; APOPTOSIS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-21 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; UP-REGULATION;

MLCS; MLOWN;

EID: 84875768393     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-37.
2. ETTINGER R, SIMS GP, ROBBINS R et al.: IL- 21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007; 178: 2872-82.
3. ETTINGER R, KUCHEN S, LIPSKY PE: The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008; 223: 60-86.
4. BUBIER JA, SPROULE TJ, FOREMAN O et al.: A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009; 106: 1518-23.
5. HERBER D, BROWN TP, LIANG S, YOUNG DA, COLLINS M, DUNUSSI-JOANNOPOULOS K: IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J Immunol 2007; 178: 3822-30.
6. SAWALHA AH, KAUFMAN KM, KELLY JA et al.: Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 458-61.
7. PASARE C, MEDZHITOV R: Control of Bcell responses by Toll-like receptors. Nature 2005; 438: 364-8.
8. PAPADIMITRAKI ED, CHOULAKI C, KOUTALA E et al.: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601-11.
9. KUCHEN S, ROBBINS R, SIMS GP et al.: Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007; 179: 5886-96.
10. SPOLSKI R, LEONARD WJ: Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79.
11. BRYANT VL, MA CS, AVERY DT et al.: Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007; 179: 8180-90.
12. ODEGARD JM, MARKS BR, DIPLACIDO LD et al.: ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 2008; 205: 2873-86.
13. SIMPSON N, GATENBY PA, WILSON A et al.: Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010; 62: 234-44.
14. MEHTA DS, WURSTER AL, WHITTERS MJ, YOUNG DA, COLLINS M, GRUSBY MJ: IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 2003; 170: 4111-8.
15. JIN H, CARRIO R, YU A, MALEK TR: Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004; 173: 657-65.
16. GOOD KL, BRYANT VL, TANGYE SG: Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006; 177: 5236-47.
17. KONFORTE D, PAIGE CJ: Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 2006; 177: 8381-92.
18. JACOBI AM, ODENDAHL M, REITER K et al.:Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332-42.
19. JACOBI AM, REITER K, MACKAY M et al.: Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58: 1762-73.
20. ODENDAHL M, JACOBI A, HANSEN A et al.: Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-9.
21. NAKANO S, MORIMOTO S, SUZUKI J et al.: Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47: 145-9.
22. WEBB R, MERRILL JT, KELLY JA et al.: A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2402-7.
23. MEHTA DS, WURSTER AL, GRUSBY MJ: Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004; 202: 84-95.
24. NEUBERT K, MEISTER S, MOSER K et al.: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.